HTL Biotechnology Acquires Modern Meadow's Human Recombinant Collagen Platform
May 8, 2024, 3:42 pm
Location: United States, District of Columbia, Washington
Employees: 501-1000
Founded date: 1984
HTL Biotechnology, a global leader in biopolymers, makes a strategic move by acquiring Modern Meadow's beauty and biomedical division, including the advanced human recombinant collagen platform. This acquisition propels HTL Biotechnology into the forefront of the cosmetic and medical industries, offering innovative solutions and expanding its portfolio.
HTL Biotechnology's acquisition of Modern Meadow's platform signifies a significant step towards driving innovation in various therapeutic areas, such as aesthetic medicine, rheumatology, and ophthalmology. By combining their expertise in GMP biofermentation with Modern Meadow's cutting-edge technology, HTL Biotechnology aims to develop disruptive innovations that will revolutionize the market.
With this acquisition, HTL Biotechnology now boasts a diverse range of products, including pharmaceutical-grade hyaluronic acid, polynucleotides, and the newly acquired human recombinant collagens. This expansion not only strengthens the company's presence in North America but also enhances its global reach and capabilities.
François Fournier, CEO of HTL Biotechnology, expresses his excitement about the acquisition, highlighting the company's commitment to innovation and client satisfaction. He sees this strategic move as a way to further solidify HTL Biotechnology's position as a pioneer in the biopolymer industry, building on their legacy of excellence in hyaluronic acid production.
Paul Navarre, Chairman of HTL Biotechnology, emphasizes the significance of this acquisition in accelerating the company's development, expanding its international footprint, and diversifying its product portfolio. This move reinforces HTL Biotechnology's leadership in biopolymers, showcasing their commitment to offering innovative solutions to meet the evolving needs of the market.
HTL Biotechnology's acquisition of Modern Meadow's human recombinant collagen platform marks a new chapter in the company's journey towards driving innovation, expanding its product offerings, and solidifying its position as a global leader in the biopolymer industry. With a focus on sustainability, ethical practices, and cutting-edge technology, HTL Biotechnology is poised to shape the future of beauty and biomedical applications.
HTL Biotechnology's acquisition of Modern Meadow's platform signifies a significant step towards driving innovation in various therapeutic areas, such as aesthetic medicine, rheumatology, and ophthalmology. By combining their expertise in GMP biofermentation with Modern Meadow's cutting-edge technology, HTL Biotechnology aims to develop disruptive innovations that will revolutionize the market.
With this acquisition, HTL Biotechnology now boasts a diverse range of products, including pharmaceutical-grade hyaluronic acid, polynucleotides, and the newly acquired human recombinant collagens. This expansion not only strengthens the company's presence in North America but also enhances its global reach and capabilities.
François Fournier, CEO of HTL Biotechnology, expresses his excitement about the acquisition, highlighting the company's commitment to innovation and client satisfaction. He sees this strategic move as a way to further solidify HTL Biotechnology's position as a pioneer in the biopolymer industry, building on their legacy of excellence in hyaluronic acid production.
Paul Navarre, Chairman of HTL Biotechnology, emphasizes the significance of this acquisition in accelerating the company's development, expanding its international footprint, and diversifying its product portfolio. This move reinforces HTL Biotechnology's leadership in biopolymers, showcasing their commitment to offering innovative solutions to meet the evolving needs of the market.
HTL Biotechnology's acquisition of Modern Meadow's human recombinant collagen platform marks a new chapter in the company's journey towards driving innovation, expanding its product offerings, and solidifying its position as a global leader in the biopolymer industry. With a focus on sustainability, ethical practices, and cutting-edge technology, HTL Biotechnology is poised to shape the future of beauty and biomedical applications.